title: Gemtuzumab ozogamicin, mitoxantrone, and etoposide in newly diagnosed acute myeloid leukemia patients with persistent leukemia after a course of induction therapy.
authors.forename: Michael
authors.initials: M
authors.lastname: Boyiadzis
authors.forename: Robert L
authors.initials: RL
authors.lastname: Redner
authors.forename: Anastasios
authors.initials: A
authors.lastname: Raptis
authors.forename: Jing-Zhou
authors.initials: JZ
authors.lastname: Hou
authors.forename: Mounzer
authors.initials: M
authors.lastname: Agha
authors.forename: Kenneth A
authors.initials: KA
authors.lastname: Foon
mesh_terms: D000328:Adult; D000617:Aminoglycosides / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D056736:Drug Recalls; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D005047:Etoposide / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D000079982:Gemtuzumab; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000175:diagnosis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage* / Q000009:adverse effects; D012074:Remission Induction; D028761:Withholding Treatment
chemical_list: D000617:Aminoglycosides; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D005047:Etoposide; D000079982:Gemtuzumab; D008942:Mitoxantrone